Treatment of autoimmune disorders with oral interferon
Autoimmune disorders are treated by the administration of human interferon, particularly IFN-.alpha. or IFN-.beta., at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The interferon is administered in a solid dosage form, e.g., a saliva-dissolvable lozenge.
Latest The Texas A&M University System Patents:
Claims
1. A method for treating a human patient afflicted with an autoimmune disorder characterized by chronic inflammatory tissue degeneration, the method consisting essentially of the steps of:
- introducing a saliva-soluble dosage form of interferon into the mouth of the patient,
- allowing the solid dosage form to dissolve in the mouth to form an interferon-containing solution, and
- contacting the interferon-containing solution with the oral and pharyngeal mucosa;
2. The method of claim 1 wherein the administered interferon is human alpha-interferon.
3. The method of claim 2 wherein the interferon is administered at a dosage of about 0.1 to about 4.0 IU/lb of patient body weight per day.
4. The method of claim 1 wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, nasal solar dermatitis, and lupus erythematosus.
5. The method of claim 1 wherein human alpha-interferon is administered to the human patient at a dosage of about 0.5 to about 1.5 IU/lb of patient body weight per day.
6. The method of claim 1 wherein the administered interferon is human beta-interferon.
7. The method of claim 1 wherein the solid dosage form is a lozenge.
8. The method of claim 2 wherein the solid dosage form is a lozenge.
9. The method of claim 3 wherein the solid dosage form is a lozenge.
10. The method of claim 4 wherein the solid dosage form is a lozenge.
11. The method of claim 5 wherein the solid dosage form is a lozenge.
12. The method of claim 6 wherein the solid dosage form is a lozenge.
13. A method for treating a human patient afflicted with an autoimmune disorder characterized by chronic inflammatory tissue degeneration, the method comprising the steps of:
- introducing a saliva-soluble dosage form of interferon into the mouth of the patient,
- allowing the solid dosage form to dissolve in the mouth to form an interferon-containing solution, and
- contacting the interferon-containing solution with the oral and pharyngeal mucosa;
14. The method of claim 13 wherein the interferon is administered at a dosage of about 0.1 to about 4.0 IU/lb of patient body weight per day.
15. The method of claim 13 wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, nasal solar dermatitis, and lupus erythematosus.
16. The method of claim 13 wherein human alpha-interferon is administered to the human patient at a dosage of about 0.5 to about 1.5 IU/lb of patient body weight per day.
17. The method of claim 13 wherein the administered interferon is human alpha-interferon.
18. The method of claim 17 wherein the saliva soluble dosage form is a lozenge.
| 3906092 | September 1975 | Hilleman et al. |
| 4053582 | October 11, 1977 | Stickl |
| 4273703 | June 16, 1981 | Osther et al. |
| 4276282 | June 30, 1981 | Sugimoto et al. |
| 4460574 | July 17, 1984 | Yabrov |
| 4462985 | July 31, 1984 | Cummins, Jr. |
| 4465702 | August 14, 1984 | Eastman et al. |
| 4496537 | January 29, 1985 | Kwan |
| 4497795 | February 5, 1985 | Cummins |
| 4507281 | March 26, 1985 | Asculai et al. |
| 4605555 | August 12, 1986 | Sato et al. |
| 4675184 | June 23, 1987 | Hasegawa et al. |
| A-48408/85 | July 1985 | AUX |
| 4841285 | April 1986 | AUX |
| 0107498 | May 1984 | EPX |
| 0177342 | April 1986 | EPX |
| 0180737 | May 1986 | DEX |
| 60-116631 | June 1985 | JPX |
| PCT/US81/01103 | August 1981 | WOX |
| WO 82/00588 | March 1982 | WOX |
| WO 83/01198 | April 1983 | WOX |
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Dec 8, 1998
Assignee: The Texas A&M University System (College Station, TX)
Inventor: Joseph M. Cummins (Amarillo, TX)
Primary Examiner: David L. Fitzgerald
Law Firm: Barnes & Thornburg
Application Number: 8/476,621
International Classification: A61K 3821;
